KR20230107807A - 의료 요법을 위한 신생기질을 분해하는 트리시클릭 화합물 - Google Patents
의료 요법을 위한 신생기질을 분해하는 트리시클릭 화합물 Download PDFInfo
- Publication number
- KR20230107807A KR20230107807A KR1020237015799A KR20237015799A KR20230107807A KR 20230107807 A KR20230107807 A KR 20230107807A KR 1020237015799 A KR1020237015799 A KR 1020237015799A KR 20237015799 A KR20237015799 A KR 20237015799A KR 20230107807 A KR20230107807 A KR 20230107807A
- Authority
- KR
- South Korea
- Prior art keywords
- certain embodiments
- compound
- formula
- alkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
- C07D209/92—Naphthostyrils
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063091894P | 2020-10-14 | 2020-10-14 | |
| US63/091,894 | 2020-10-14 | ||
| PCT/US2021/055104 WO2022081927A1 (en) | 2020-10-14 | 2021-10-14 | Tricyclic compounds to degrade neosubstrates for medical therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230107807A true KR20230107807A (ko) | 2023-07-18 |
Family
ID=81208653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237015799A Pending KR20230107807A (ko) | 2020-10-14 | 2021-10-14 | 의료 요법을 위한 신생기질을 분해하는 트리시클릭 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240018118A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4228624A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7863101B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230107807A (cg-RX-API-DMAC10.html) |
| CN (2) | CN122277521A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021360596A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3194351A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL302036A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023004369A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022081927A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| JP7863100B2 (ja) * | 2020-10-14 | 2026-05-20 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
| JP7807110B2 (ja) * | 2021-08-27 | 2026-01-27 | ハンチョウ グルビオ ファーマシューティカル カンパニー,リミティド | イソインドリノン化合物およびその使用 |
| JP2025501056A (ja) | 2021-12-30 | 2025-01-17 | シャンハイ ハンソー バイオメディカル カンパニー リミテッド | 三環系誘導体阻害剤、その製造方法と応用 |
| JP2025531869A (ja) * | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | CK1αおよびDUAL CK1α/GSPT1分解化合物 |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| KR20250079173A (ko) | 2022-10-03 | 2025-06-04 | 고리츠다이가쿠호진 요코하마시리츠다이가쿠 | 이환성 구조를 갖는 이미다조피리딘 유도체 |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2024153246A1 (zh) * | 2023-01-20 | 2024-07-25 | 海南先声再明医药股份有限公司 | 取代的三环化合物及其应用 |
| CN120569372A (zh) | 2023-01-24 | 2025-08-29 | 第一三共株式会社 | 经取代的苯化合物 |
| CN117903192A (zh) * | 2023-03-12 | 2024-04-19 | 上海相辉医药科技有限公司 | 一种3-甲氧基异喹啉化合物中间体的制备方法 |
| WO2024259303A1 (en) * | 2023-06-16 | 2024-12-19 | Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs | Compounds and compositions as cereblon ligands and uses thereof |
| TW202530189A (zh) | 2023-09-29 | 2025-08-01 | 日商第一三共股份有限公司 | 3-苯基丙基胺衍生物 |
| WO2025162410A1 (zh) * | 2024-01-31 | 2025-08-07 | 微境生物医药科技(上海)有限公司 | 新型蛋白降解剂及抗体-蛋白降解剂偶联物 |
| CN121620373A (zh) * | 2024-07-26 | 2026-03-06 | 上海超阳药业有限公司 | 苯并吲哚衍生物的药物组合物、制备方法及用途 |
| TW202615052A (zh) * | 2024-08-27 | 2026-04-16 | 日商第一三共股份有限公司 | 多環性化合物 |
| WO2026064643A1 (en) * | 2024-09-20 | 2026-03-26 | Plexium, Inc. | Compounds, compositions, and methods of use thereof |
| WO2026065268A1 (en) * | 2024-09-29 | 2026-04-02 | Biofront Ltd | Novel conjugates for protein degradation, compositions comprising the same, and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007517766A (ja) * | 2003-09-24 | 2007-07-05 | コンビナトアールエックス インコーポレーティッド | 薬物の組み合わせを投与するための治療法 |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| CN111662226B (zh) * | 2015-01-28 | 2022-03-18 | 中国科学院广州生物医药与健康研究院 | 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物 |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| US10738056B2 (en) * | 2017-09-15 | 2020-08-11 | Aduro Biotech Inc. | Pyrazolopyrimidinone compounds and uses thereof |
| JP2021512153A (ja) * | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| US10905684B2 (en) * | 2018-06-13 | 2021-02-02 | Biotheryx, Inc. | Aminoamide compounds |
| US12030892B2 (en) * | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3123519A1 (en) * | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| KR102947433B1 (ko) * | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| CN116194453A (zh) * | 2019-12-20 | 2023-05-30 | 卡里科生命科学有限责任公司 | 蛋白质酪氨酸磷酸酶降解剂及其使用方法 |
| AU2021322285B2 (en) * | 2020-08-07 | 2026-08-13 | C4 Therapeutics, Inc. | Advantageous therapies for disorders mediated by Ikaros or Aiolos |
| JP7863100B2 (ja) * | 2020-10-14 | 2026-05-20 | シーフォー セラピューティクス, インコーポレイテッド | Ikzf2又はikzf4を分解する三環式リガンド |
| IL302037A (en) * | 2020-10-14 | 2023-06-01 | C4 Therapeutics Inc | Tricyclic heterobifunctional compounds for degradation of targeted proteins |
-
2021
- 2021-10-14 CA CA3194351A patent/CA3194351A1/en active Pending
- 2021-10-14 WO PCT/US2021/055104 patent/WO2022081927A1/en not_active Ceased
- 2021-10-14 CN CN202610392389.1A patent/CN122277521A/zh active Pending
- 2021-10-14 AU AU2021360596A patent/AU2021360596A1/en active Pending
- 2021-10-14 JP JP2023523013A patent/JP7863101B2/ja active Active
- 2021-10-14 EP EP21881144.6A patent/EP4228624A4/en active Pending
- 2021-10-14 IL IL302036A patent/IL302036A/en unknown
- 2021-10-14 KR KR1020237015799A patent/KR20230107807A/ko active Pending
- 2021-10-14 MX MX2023004369A patent/MX2023004369A/es unknown
- 2021-10-14 CN CN202180079148.7A patent/CN116457339A/zh active Pending
-
2023
- 2023-04-14 US US18/134,990 patent/US20240018118A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021360596A1 (en) | 2023-06-08 |
| JP2023545509A (ja) | 2023-10-30 |
| WO2022081927A1 (en) | 2022-04-21 |
| EP4228624A4 (en) | 2025-04-23 |
| CN122277521A (zh) | 2026-06-26 |
| CA3194351A1 (en) | 2022-04-21 |
| EP4228624A1 (en) | 2023-08-23 |
| JP7863101B2 (ja) | 2026-05-20 |
| CN116457339A (zh) | 2023-07-18 |
| US20240018118A1 (en) | 2024-01-18 |
| IL302036A (en) | 2023-06-01 |
| AU2021360596A9 (en) | 2024-02-08 |
| MX2023004369A (es) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240018118A1 (en) | Tricyclic compounds to degrade neosubstrates for medical therapy | |
| US12049464B2 (en) | Compounds for targeted degradation of BRD9 | |
| US20230372496A1 (en) | Tricyclic heterobifunctional compounds for degradation of targeted proteins | |
| JP7863100B2 (ja) | Ikzf2又はikzf4を分解する三環式リガンド | |
| JP7846819B2 (ja) | Ikaros及びAiolosの三環式分解誘導薬 | |
| EP4735438A2 (en) | Heterobifunctional compounds for the degradation of kras | |
| IL298294B1 (en) | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders | |
| JP2025540906A (ja) | Ret-lddタンパク質阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |